tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings

Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings

Syndax Pharmaceuticals Inc. (SNDX) has disclosed a new risk, in the Regulation category.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Syndax Pharmaceuticals Inc. faces significant business risks and uncertainties as outlined in their 2024 Form 10-K and Q1 2025 Form 10-Q reports filed with the SEC. These documents highlight potential factors that could materially and adversely impact the company’s business, prospects, financial condition, and operational results. Despite no material changes in risk factors since these filings, new risks may emerge, and unknown or currently deemed immaterial risks could also affect the company adversely. Stakeholders should consider these disclosures carefully when evaluating Syndax Pharmaceuticals’ future outlook.

The average SNDX stock price target is $35.10, implying 179.24% upside potential.

To learn more about Syndax Pharmaceuticals Inc.’s risk factors, click here.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1